On December 15, 2020, Genentech led a discussion about how the Most Favored Nations (MFN) model threatens provider and patient access to existing and future medicines; we share your concerns that this could have a detrimental impact on your practice and ability to treat patients. Genentech agrees that we have to work together across the healthcare delivery system to enable all Americans to receive appropriate and affordable care. As we do this, we must protect and sustain patient access to scientific innovation in the U.S. so that people with serious diseases continue to benefit from the breakthrough medicines they depend on. Never has this need been clearer than during the current COVID-19 pandemic.
Below is more information on the MFN model, Genentech’s position, as well as that of other organizations.
- HHS Press Release on MFN interim final rule
- Health Affairs Blog, “Administration Finalizes Most-Favored Nation Drug Pricing Rule At The Last Minute”
- Genentech statement on President Trump’s MFN Executive Order, and Genentech pricing philosophy
- Association statements: PhRMA, BIO, Community Oncology Alliance, American Hospital Association, American Cancer Society – Cancer Action Network
If you would like to independently advocate against this model, I suggest that you reach out to your physician specialty societies and ask them to:
- Engage policymakers, in Congress and in the current and incoming administrations, to stop the implementation of MFN;
- Communicate their concern to CMS via written comments; and
- Consider joining or pursuing litigation challenging implementation of MFN. The most expedient way to get societies involved in existing cases is for them to contact representatives at PhRMA (PHRMA_alliance@phrma.org) or BIO (email@example.com).
Additionally, you can reach out to your federal and state representatives, to request that they weigh in opposing the model with their peers, and existing and incoming administration officials.